-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LePjc54e6XLOXYyjoRue4y4Oz0L0U0OTsLnzvcoCDn62UkaSTLAC2AuPsqb/JHmh 4i6zzxXzqTEY/jtCtVeg/A== 0001104659-10-009345.txt : 20100225 0001104659-10-009345.hdr.sgml : 20100225 20100225070754 ACCESSION NUMBER: 0001104659-10-009345 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20100225 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20100225 DATE AS OF CHANGE: 20100225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRUKER CORP CENTRAL INDEX KEY: 0001109354 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 043110160 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30833 FILM NUMBER: 10631529 BUSINESS ADDRESS: STREET 1: 40 MANNING RD CITY: BILLERICA STATE: MA ZIP: 01821 BUSINESS PHONE: 978663-3660 MAIL ADDRESS: STREET 1: 40 MANNING RD CITY: BILLERICA STATE: MA ZIP: 01821 FORMER COMPANY: FORMER CONFORMED NAME: BRUKER BIOSCIENCES CORP DATE OF NAME CHANGE: 20030721 FORMER COMPANY: FORMER CONFORMED NAME: BRUKER DALTONICS INC DATE OF NAME CHANGE: 20000315 8-K 1 a10-3190_28k.htm 8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 193
4

 


 

Date of Report (Date of earliest event reported): February 25, 2010

 

BRUKER CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware
(State or other jurisdiction
of incorporation)

 

000-30833
(Commission
File Number)

 

04-3110160
(IRS Employer
Identification No.)

 

40 Manning Road
Billerica, MA 01821
(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code: (978) 663-3660

 

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the reporting obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act

 

o Soliciting material pursuant to Rule 14a-12 of the Exchange Act

 

o Pre-commencement communications pursuant to Rule 14d-2(b) Exchange Act

 

o Pre-commencement communications pursuant to Rule 13e-4(c) Exchange Act

 

 

 



 

Section 2 – Financial Information

 

Item 2.02.  Results of Operations and Financial Condition

 

On February 25, 2010, Bruker Corporation issued a press release announcing combined financial results as of and for the three and twelve months ended December 31, 2009.  A copy of the press release is attached hereto as Exhibit 99.1.

 

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

2



 

Section 9 – Financial Statements and Exhibits

 

Item 9.01.  Financial Statements and Exhibits.

 

(d)

Exhibits

 

 

 

 

 

Number

 

 

 

 

 

  99.1

Press release dated February 25, 2010.

 

3



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BRUKER CORPORATION

 

(Registrant)

 

 

 

Date: February 25, 2010

By:

/s/ BRIAN P. MONAHAN

 

 

Brian P. Monahan

 

 

Chief Financial Officer

 

4



 

Exhibit Index

 

Exhibit
Number

 

Exhibit Name

 

Location

 

 

 

 

 

99.1

 

Press release dated February 25, 2010.

 

Furnished herewith*

 


*   Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

5


EX-99.1 2 a10-3190_2ex99d1.htm EX-99.1

Exhibit 99.1

 

Bruker Corporation Reports Record Financial Results for the Fourth Quarter and Full Year 2009

 

BILLERICA, Mass., February 25, 2010 (BUSINESS WIRE)  —  Bruker Corporation (NASDAQ: BRKR) today reported financial results for the fourth quarter and year ended December 31, 2009.

 

Q4 Highlights

 

Q4-09

 

Q4-08

·

Revenue:

 

$366.4 million

 

$315.2 million

·

GAAP EPS per diluted share:

 

$0.26

 

$0.16

·

Operating Cash Flow:

 

$82.5 million

 

$88.0 million

 

Full-Year Highlights

 

FY-09

 

FY-08

·

Revenue:

 

$1.114 billion

 

$1.107 billion

·

GAAP EPS per diluted share:

 

$0.49

 

$0.39

·

Operating Cash Flow:

 

$149.8 million

 

$106.9 million

 

Financial Results

 

In the fourth quarter of 2009, GAAP revenue increased by 16% to $366.4 million, compared to revenue of $315.2 million in the fourth quarter of 2008.  Excluding the effects of foreign currency translation, fourth quarter revenue increased by 6% year-over-year.  In the fourth quarter of 2009, GAAP revenue increased by 13% year-over-year for the Bruker Scientific Instruments (BSI) segment, and by 116% year-over-year for the Bruker Energy & Supercon Technologies (BEST) segment.

 

GAAP operating income in the fourth quarter of 2009 was $76.2 million, compared to $48.9 million in the fourth quarter of 2008.  GAAP net income for the fourth quarter of 2009 was $43.5 million, or $0.26 per diluted share, compared to $26.2 million, or $0.16 per diluted share, in the fourth quarter of 2008.  Included in GAAP EPS for the fourth quarter 2009 was non-cash stock-based compensation expense of ($0.01) per diluted share, the same as in the fourth quarter of 2008.

 

For the year 2009, GAAP revenue increased by 1% to $1,114.5 million, compared to revenue of $1,107.1 million for the year 2008.  Excluding the effects of foreign currency translation, full year 2009 revenue increased by 2% year-over-year.  For the year 2009, GAAP revenue decreased 1% to $1,062.7 million for the BSI segment, and increased 37% to $59.8 million for the BEST segment, compared to the year 2008.

 

For the year 2009, GAAP operating income was $136.7 million, compared to $108.2 million for the year 2008.  Operating income for the BSI segment in 2009 was $141.7 million, compared to $116.2 million in 2008.  In the year 2009, BSI operating income was favorably impacted by $6.7 million, or by 60 basis points, upon recognizing revenue for the world’s first 1 GHz NMR system, for which the majority of R&D expenses were

 



 

recorded prior to 2009.

 

For the year 2009, GAAP net income was $81.2 million, or $0.49 per diluted share, compared to $64.9 million, or $0.39 per diluted share, in 2008.  Included in GAAP EPS for the full year 2009 was non-cash stock-based compensation expense of ($0.03) per diluted share, compared to ($0.02) per diluted share for 2008.  For the year 2009, the BSI segment contributed GAAP earnings of $0.53 per diluted share, compared to $0.44 in 2008.  For the year 2009, the BEST segment contributed a GAAP loss of ($0.04) per diluted share, compared to ($0.05) in 2008.

 

Cash flow from operations for the full year 2009 was $149.8 million, compared to $106.9 million in 2008.  Free cash flow, defined as operating cash flow less capital expenditures, was $131.7 million during 2009, compared to $59.5 million during 2008.  During the year 2009, the Company repaid $86.1 million of debt, and as of December 31, 2009, Bruker had cash, cash equivalents and restricted cash of $209.1 million and net cash of $71.4 million.

 

Comment and Outlook

 

Frank Laukien, President and CEO, commented: “Given the challenging economic conditions in 2009, we are extremely pleased that we could exceed our full-year 2009 financial goals with year-over-year

 

·                  currency-adjusted total revenue growth of 2%,

·                  BSI improvement in GAAP operating margin of 250 basis points,

·                  BSI increase in GAAP net income of 19%,

plus excellent improvements in cash flow.

 

This success is directly attributable to the strength of our high-performance, innovative scientific instruments and analytical solutions portfolio, as well as to the enthusiasm and customer focus of our global Bruker team.

 

Moreover, we are also pleased with the recent acceleration in growth of BEST, which more than doubled its fourth quarter 2009 revenue year-over-year.  We are optimistic about the prospects for this ‘intrapreneurial’ venture, as BEST further develops its broad technology base in superconducting materials and devices, in order to address potentially large emerging markets in clean tech, alternative energy and ‘big science’ infrastructure.”

 

Dr. Laukien continued: “In 2010, as Bruker celebrates its 50th anniversary, our goal is to build on our success over the past 50 years by remaining true to our innovation and profitable growth strategy.  We believe that our commitment to R&D and customer focus, coupled with emphasis on operational excellence, can generate further improvements in financial performance.  Our financial goals for the year 2010 are:

 

·                  total Bruker currency-adjusted revenue growth of greater than 5%,

 



 

·                  BSI operating margin improvement of greater than 125 basis points, excluding the 60 basis point favorable impact from the 1 GHz NMR recognized in 2009,

·                  BSI net income and EPS increase of greater than 15%, and

·                  BSI working capital decrease of more than 5%.

 

For our BEST segment, in 2010 we plan greater than 25% revenue growth, continued infrastructure, marketing and R&D investments for clean-tech and alternative energy applications, with an expected BEST 2010 operating loss of $7-8 million.”

 

EARNINGS CONFERENCE CALL

 

Bruker Corporation will host an operator-assisted earnings conference call at 9:00 a.m. Eastern Time on Thursday, February 25, 2010.  To listen to the webcast, investors can go to http://ir.bruker.com and click on the live web broadcast symbol.  The webcast will be available through the Company web site for 30 days.  Investors can also listen and participate on the telephone in the US and Canada by calling 800-688-0796, or +1-617-614-4070 outside the US and Canada.  Investors should refer to the Bruker Earnings Call.  A telephone replay of the conference call will be available one hour after the conference call by dialing 888-286-8010 in the US and Canada, or +1-617-801-6888 outside the US and Canada, and then entering replay pass code 24438469.  For more information, please visit http://ir.bruker.com

 

CAUTIONARY STATEMENT

 

Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, realization of anticipated benefits from economic stimulus programs, intellectual property rights, litigation, and exposure to foreign currency fluctuations and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our recent Proxy Statements on Schedule 14A, our annual report on Form 10-K for the year ended December 31, 2008, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

 



 

Bruker Corporation

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in millions, except per share data)

 

 

 

Three Months Ended December 31,

 

Twelve Months Ended December 31,

 

 

 

2009

 

2008

 

2009

 

2008

 

 

 

 

 

 

 

 

 

 

 

Product revenue

 

$

329.5

 

$

274.5

 

$

985.3

 

$

974.9

 

Service revenue

 

34.8

 

39.2

 

122.4

 

126.9

 

Other revenue

 

2.1

 

1.5

 

6.8

 

5.3

 

Total revenue

 

366.4

 

315.2

 

1,114.5

 

1,107.1

 

 

 

 

 

 

 

 

 

 

 

Cost of product revenue

 

160.4

 

145.2

 

525.2

 

527.5

 

Cost of service revenue

 

20.5

 

19.7

 

70.7

 

74.6

 

Total cost of revenue

 

180.9

 

164.9

 

595.9

 

602.1

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

185.5

 

150.3

 

518.6

 

505.0

 

 

 

 

 

 

 

 

 

 

 

Operating Expenses:

 

 

 

 

 

 

 

 

 

Sales and marketing

 

55.2

 

47.1

 

185.8

 

183.8

 

General and administrative

 

18.7

 

19.0

 

69.5

 

70.7

 

Research and development

 

34.6

 

33.0

 

126.4

 

133.8

 

Restructuring charges

 

 

2.3

 

 

2.3

 

Acquisition related, net

 

0.8

 

 

0.2

 

6.2

 

Total operating expenses

 

109.3

 

101.4

 

381.9

 

396.8

 

 

 

 

 

 

 

 

 

 

 

Operating income

 

76.2

 

48.9

 

136.7

 

108.2

 

 

 

 

 

 

 

 

 

 

 

Interest and other income (expense), net

 

(3.0

)

(7.2

)

(7.6

)

(15.0

)

 

 

 

 

 

 

 

 

 

 

Income before income taxes and noncontrolling interest in consolidated subsidiaries

 

73.2

 

41.7

 

129.1

 

93.2

 

Income tax provision

 

29.6

 

15.5

 

48.1

 

28.0

 

 

 

 

 

 

 

 

 

 

 

Net income

 

43.6

 

26.2

 

81.0

 

65.2

 

Net income (loss) attributable to noncontrolling interests

 

0.1

 

 

(0.2

)

0.3

 

Net income attributable to Bruker Corporation

 

$

43.5

 

$

26.2

 

$

81.2

 

$

64.9

 

 

 

 

 

 

 

 

 

 

 

Net income per common share attributable to:

 

 

 

 

 

 

 

 

 

Bruker Corporation shareholders:

 

 

 

 

 

 

 

 

 

Basic

 

$

0.27

 

$

0.16

 

$

0.50

 

$

0.40

 

Diluted

 

$

0.26

 

$

0.16

 

$

0.49

 

$

0.39

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding:

 

 

 

 

 

 

 

 

 

Basic

 

163.8

 

163.1

 

163.5

 

162.7

 

Diluted

 

165.2

 

164.6

 

164.9

 

165.6

 

 



 

Bruker Corporation

CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions)

 

 

 

December 31,

 

December 31,

 

 

 

2009

 

2008

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash, cash equivalents and restricted cash

 

$

209.1

 

$

167.7

 

Accounts receivable, net

 

184.1

 

171.9

 

Inventories

 

422.8

 

425.1

 

Other current assets

 

57.5

 

56.0

 

Total current assets

 

873.5

 

820.7

 

 

 

 

 

 

 

Property and equipment, net

 

223.4

 

221.3

 

Intangible and other assets

 

75.1

 

74.3

 

 

 

 

 

 

 

Total assets

 

$

1,172.0

 

$

1,116.3

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Short-term borrowings

 

$

22.0

 

$

41.0

 

Accounts payable

 

49.8

 

43.3

 

Customer deposits

 

219.2

 

199.6

 

Other current liabilities

 

248.1

 

235.8

 

Total current liabilities

 

539.1

 

519.7

 

 

 

 

 

 

 

Long-term debt

 

115.7

 

182.8

 

Other long-term liabilities

 

98.4

 

101.1

 

 

 

 

 

 

 

Total shareholders’ equity

 

418.8

 

312.7

 

 

 

 

 

 

 

Total liabilities and shareholders’ equity

 

$

1,172.0

 

$

1,116.3

 

 



 

Reconciliation of BSI and BEST reportable segments to the consolidated results of Bruker Corporation for the twelve months ended December 31, 2009 and 2008 (unaudited)

(in millions, except per share data)

 

 

 

 

 

Bruker

 

 

 

 

 

 

 

Bruker

 

Energy &

 

Corporate,

 

 

 

 

 

Scientific

 

Supercon

 

Adjustments

 

GAAP

 

 

 

Instruments

 

Technologies

 

& Eliminations

 

Consolidated

 

December 31, 2009:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

1,062.7

 

$

59.8

 

$

(8.0

)

$

1,114.5

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss)

 

141.7

 

(6.3

)

1.3

 

136.7

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

87.2

 

(6.9

)

0.9

 

81.2

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per diluted share

 

$

0.53

 

$

(0.04

)

$

0.01

 

$

0.49

 

Diluted Shares Outstanding

 

164.9

 

163.5

 

164.9

 

164.9

 

 

 

 

 

 

 

 

 

 

 

December 31, 2008:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

1,074.1

 

$

43.5

 

$

(10.5

)

$

1,107.1

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss)

 

116.2

 

(8.2

)

0.2

 

108.2

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

73.5

 

(8.9

)

0.3

 

64.9

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per diluted share

 

$

0.44

 

$

(0.05

)

$

0.00

 

$

0.39

 

Diluted Shares Outstanding

 

165.6

 

162.7

 

165.6

 

165.6

 

 

FOR FURTHER INFORMATION:

Stacey Desrochers, Director of Investor Relations

 

Tel: +1 (978) 663-3660, ext. 1115

 

Email:  stacey.desrochers@bruker.com

 


-----END PRIVACY-ENHANCED MESSAGE-----